K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratificationAndrew S. Levey, Antonio M. Gotto, Josef Coresh et al.|Data Archiving and Networked Services (DANS)|2002Cited by 11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesBruce Neal, David R. Matthews, Vlado Perkovic et al.|New England Journal of Medicine|2017Cited by 7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Meg Jardine et al.|New England Journal of Medicine|2019Cited by 6k
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Andrew S. Levey, Garabed Eknoyan, Kai‐Uwe Eckardt et al.|Kidney International|2005Cited by 3.9k
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney diseaseShaul G. Massry, John M. Newmann, Jerrilynn D. Burrowes et al.|Data Archiving and Networked Services (DANS)|2003Cited by 2.5k